3-methyl-1,2,3,4-tetrahydroquinazolin-2-one

CAS No. 24365-65-9

3-methyl-1,2,3,4-tetrahydroquinazolin-2-one( —— )

Catalog No. M28377 CAS No. 24365-65-9

3-methyl-1,2,3,4-tetrahydroquinazolin-2-one is a inhibitor of BRD4 .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 51 In Stock
2MG 31 In Stock
5MG 48 In Stock
10MG 71 In Stock
25MG 122 In Stock
50MG 179 In Stock
100MG 267 In Stock
200MG Get Quote In Stock
500MG 663 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    3-methyl-1,2,3,4-tetrahydroquinazolin-2-one
  • Note
    Research use only, not for human use.
  • Brief Description
    3-methyl-1,2,3,4-tetrahydroquinazolin-2-one is a inhibitor of BRD4 .
  • Description
    3-methyl-1,2,3,4-tetrahydroquinazolin-2-one is a inhibitor of BRD4 .
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Platelet aggregation
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    24365-65-9
  • Formula Weight
    162.192
  • Molecular Formula
    C9H10N2O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CN1Cc2ccccc2NC1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Jian Tang, et al. Antitumor and antiplatelet activity of alkaloids from veratrum dahuricum. Phytother Res. 2010 Jun;24(6):821-6.
molnova catalog
related products
  • ZEN-3411

    ZEN-3411 is an orally available and potent BET inhibitor that inhibits BRD4(BD1), BRD4(BD2), and BRD4(BD1BD2) and suppresses the growth of tumor cells overproducing BET proteins.

  • C646

    C646 is an inhibitor for histone acetyltransferase, and inhibits p300 with a Ki of 400 nM in a cell-free assay.

  • RVX-208

    RVX-208 is a potent BET bromodomain inhibitor with IC50 of 0.510 μM for BD2 in a cell-free assay, about 170-fold selectivity over BD1. Phase 2.